AstraZeneca Agrees to Lower US Medicine Prices

Ticker: AZN · Form: 6-K · Filed: 2025-10-14T00:00:00.000Z

Sentiment: neutral

Topics: pricing-agreement, regulatory, us-market

TL;DR

AstraZeneca cuts US drug prices, filing confirms.

AI Summary

AstraZeneca PLC filed a Form 6-K on October 14, 2025, reporting an agreement with the US Government to lower medicine prices. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

Why It Matters

This agreement could impact AstraZeneca's revenue from the US market and potentially set a precedent for other pharmaceutical companies regarding drug pricing.

Risk Assessment

Risk Level: medium — The agreement to lower prices could negatively affect revenue and profitability, but the exact financial impact is not detailed in this filing.

Key Players & Entities

FAQ

What specific medicines are included in the agreement to lower prices?

The filing does not specify which medicines are included in the agreement to lower prices.

What is the effective date of the agreement to lower medicine prices?

The filing does not state the effective date of the agreement.

What is the expected financial impact of this agreement on AstraZeneca's revenue?

The filing does not provide any financial projections or estimates regarding the impact of the agreement.

Is this agreement part of a broader initiative by the US Government to control drug prices?

The filing mentions an agreement with the US Government but does not provide context on whether it's part of a broader initiative.

Does AstraZeneca file annual reports under Form 20-F?

Yes, AstraZeneca indicates it files annual reports under Form 20-F.

From the Filing

0001654954-25-011688.txt : 20251014 0001654954-25-011688.hdr.sgml : 20251014 20251014060526 ACCESSION NUMBER: 0001654954-25-011688 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251014 FILED AS OF DATE: 20251014 DATE AS OF CHANGE: 20251014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251389245 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9731c.htm AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES a9731c FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________             AstraZeneca PLC   INDEX TO EXHIBITS     1. Agreement with US Govt to lower medicine prices       13 October 2025   AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients   Delivers on all four of President Trump's requests reducing cost of medicines   Preserves America's role as a global powerhouse in biopharmaceuticals innovation   AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing   AstraZeneca today announces a historic agreement with President Donald J. Trump's administration to lower the cost of prescription medicines for American patients while preserving America's cutting-edge biopharmaceutical innovation.   At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President's 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.   As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.   AstraZeneca has also

View on Read The Filing